caa a22 4500 378926136 CHVBK 20180305123618.0 cr unu---uuuuu 161128e20040617xx s 000 0 mul 10.1515/LabMed.2004.043 doi (NATIONALLICENCE)gruyter-10.1515/LabMed.2004.043 Prognostic value of soluble interleukin-2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon alpha 2b and ribavirin [Elektronische Daten] Der prognostische Wert von Plasmaspiegeln des löslichen Interleukin-2-Rezeptors in mit pegyliertem Interferon alpha 2b und Ribavirin behandelten Non-Respondern mit chronischer Hepatitis C / [T. Griga, W. Schmiegel, H. Henke] In patients with chronic HCV infection, a significant elevation in serum levels of soluble interleukin-2 receptor has been shown. Different results have been found for the efficacy of interferon therapy. We studied the plasma levels of the soluble interleukin-2 receptor in primary non-responders who had undergone a re-treatment with pegylated interferon alpha 2b and ribavirin to evaluate the differences between responders and non-responders to this therapy. The study was performed on 15 patients with chronic HCV infection who had shown no response to primary therapy and on 15 healthy volunteers. The plasma levels of the soluble interleukin-2 receptor were determined using enzyme-linked immunosorbent assay. The patients underwent a therapy with pegylated interferon alpha 2b and ribavirin for 48 weeks. The plasma levels of the soluble interleukin-2 receptor were determined during therapy, and in the case of response, 24 weeks after therapy. Four out of 15 patients showed a sustained virological response after therapy. Before re-treatment, the soluble interleukin-2 receptor plasma levels were significantly higher in patients who showed no response to re-treatment with pegylated interferon alpha 2b/ribavirin compared with healthy controls (1552 [932−2225] pg/ml vs. 884 [489−1704] pg/ml, p = 0.003). There was no significant difference in soluble interleukin-2 receptor plasma levels before therapy between patients with sustained virological response (932 [840−1339] pg/ml) and healthy controls. Therapy had to be stopped in one patient due to thrombocytopenia. Plasma levels of the soluble interleukin-2 receptor seem to be a prognostic marker of sustained virological response in non-responders prior to a re-treatment with pegylated interferon alpha 2b and ribavirin. Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence Griga T. aut Schmiegel W. aut Henke H. aut LaboratoriumsMedizin Walter de Gruyter 28/3(2004-06-17), 288-292 0342-3026 28:3<288 2004 28 labm https://doi.org/10.1515/LabMed.2004.043 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/LabMed.2004.043 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Griga T. aut NATIONALLICENCE 700 1- Schmiegel W. aut NATIONALLICENCE 700 1- Henke H. aut NATIONALLICENCE 773 0- LaboratoriumsMedizin Walter de Gruyter 28/3(2004-06-17), 288-292 0342-3026 28:3<288 2004 28 labm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter